+44 20 8123 2220
info@marketpublishers.com

Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019

https://marketpublishers.com/r/DA90899F90ECEN.html
Date: December 2019
Pages: 44
Price: US$ 3,500.00 (Single User License)
ID: DA90899F90ECEN

Abstracts

Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019

SUMMARY

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019, outlays comprehensive information on the Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dual specificity protein kinase TTK is an enzyme encoded by the TTK gene. It is associated with cell proliferation, essential for chromosome alignment at the centromere during mitosis and is required for centrosome duplication. It acts as critical mitotic checkpoint protein for accurate segregation of chromosomes during mitosis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 5 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Triple-Negative Breast Cancer (TNBC), Metastatic Breast Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic

+44 20 8123 2220
info@marketpublishers.com

Leukemia), Colorectal Cancer, Glioblastoma Multiforme (GBM), Hormone Refractory (Castration Resistant and Androgen-Independent) Prostate Cancer.

Furthermore, this report also reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)

The report reviews Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein

+44 20 8123 2220
info@marketpublishers.com

Kinase or TTK or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) development landscape

+44 20 8123 2220
info@marketpublishers.com

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

COMPANIES MENTIONED

Bayer AG
Boston Pharmaceuticals Inc
Les Laboratoires Servier SAS
Netherlands Translational Research Center BV
NMS Group SpA
Pfizer Inc
Voronoi

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Dual Specificity Protein Kinase TTK - Pipeline Review, H2 2019

Product link: https://marketpublishers.com/r/DA90899F90ECEN.html

Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/DA90899F90ECEN.html